European Society for Medical Oncology
LUX-Lung 7 Update: Trend for OS Benefit for Afatinib
Copenhagen, Denmark—Updated results from the Phase IIb LUX-Lung 7 trial of afatinib versus gefitinib were ...
FEBRUARY 3, 2017
Novel Second-Line Therapies Offer Benefit in HCC
Copenhagen, Denmark—As a second-line treatment for hepatocellular carcinoma (HCC) after progression on ...
JANUARY 26, 2017
Load more